A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Scientists uncover how Ffar4 regulates sugar cravings through gut microbiota, revealing pantothenate as a key mediator to ...

Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

By 2060, 1 million adults per year will develop dementia, according to a study published in Nature Medicine. Also in the news, chronic cannabis use may lead to chronic illness; Eli Lilly hopes to ...

The series tackles the ‘GLP-1 revolution,’ created to educate consumers about the medication’s potential uses and side ...